Related Experiment Video
Updated: Oct 20, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization
Kirema Garcia-Reyes1, William H Wang2, Mufiza Farid-Kapadia2
1Division of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Aims:
To describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.
Materials & Methods:
This retrospective observational study used Optum's de-identified Market Clarity Data. US adults with HCC treated with embolization between July 2016-September 2022 were followed from first embolization following diagnosis until death and end of enrollment or study period.
Results:
Of 1,458 patients, 41.9%, 33.5%, and 24.6% received transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and transarterial embolization (TAE), respectively, as initial embolization therapy; TARE use increased over time. Most were male (74.6%), white (66.5%), with a median age at index of 65.0 years, and 63.1% required ≥1 subsequent treatment (median treatment pattern follow-up: 16.3 months). Median (95% CI) time to first follow-up treatment or death was 5.9 (5.5-6.4) months. Compared with TARE, risk of death was lower with TACE (HR [95% CI] 0.82 [0.69-0.97]; P = 0.0242], non-significant in missingness sensitivity analysis) and higher with TAE (HR [95% CI] 1.25 [1.05-1.49]; P = 0.0135]).
Conclusion:
TARE was the most common initial embolization therapy and its use increased over time. Time to first follow-up treatment or death was relatively short. Future studies are needed to identify optimal treatment approaches.
